Search Results

You are looking at 1 - 10 of 24 items for :

  • "somatostatin analog" x
Clear All
Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

; in particular those with AIP mutations have a significantly lower hormonal response to first-generation, receptor subtype 2 (SST2) specific somatostatin analogs (octreotide and lanreotide) and have a decreased rate of tumor shrinkage on treatment

Open access

Adrian F Daly, David A Cano, Eva Venegas-Moreno, Patrick Petrossians, Elena Dios, Emilie Castermans, Alvaro Flores-Martínez, Vincent Bours, Albert Beckers and Alfonso Soto-Moreno

patients may be resistant to somatostatin analogs (SSA) that target the somatostatin receptor subtype 2 (SST2), while a small proportion of prolactinoma patients may not respond to labeled doses of dopamine agonists (DA). Hence, multimodal therapy involving

Open access

Alberto Bongiovanni, Federica Recine, Flavia Foca, Valentina Fausti, Nada Riva, Greta Fabbri, Stefano Severi, Chiara Liverani, Alessandro De Vita, Chiara Spadazzi, Giacomo Miserocchi, Laura Mercatali, Dino Amadori and Toni Ibrahim

reported in <15% of cases ( 7 ). Treatment options for metastatic disease comprise liver surgery and/or locoregional and ablative therapies, somatostatin analogs, chemotherapy, targeted therapy and peptide receptor radionuclide therapy ( 8 ). Given the

Open access

Irvin M Modlin, Harry Aslanian, Lisa Bodei, Ignat Drozdov and Mark Kidd

. Disease was localized in 28% and was distant in 67%. No pathology and staging was available in 12 (10%) patients. Twenty-two percent were treatment naïve, while 26% were currently being treated with somatostatin analogs, and 9% (11 patients, all Zollinger

Open access

Merete Gedde-Dahl, Espen Thiis-Evensen, Andreas Myklebust Tjølsen, Kjerstin Skrede Mordal, Morten Vatn and Deidi S Bergestuen

.9%) Known remaining tumor 24 (71%) Disease distribution  Local/regional metastases 5/24 (21%)  Distant metastases a 19/24 (79%) Somatostatin analog use 8 (23.5%) Overnight sampling period (h) 8.3 (7

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari and S Cannavò

) and second generation (pasireotide) somatostatin analogs (SSa), and the rationale of the use of radiolabeled-SSa for diagnostic imaging and PRRT ( 111 In-pentreotide, 177 Lu-DOTA, 90 Y-DOTA, 68 Ga-DOTA) ( 8 , 9 ). Herein we report on the

Open access

Julie M Silverstein

; GH, growth hormone; GHR, growth-hormone receptor; IGF1, insulin-like growth factor 1; OGTT, oral glucose tolerance test; SSA, somatostatin analog. There are important benefits associated with the assessment of composite biochemical endpoints

Open access

Kjell Oberg, Eric Krenning, Anders Sundin, Lisa Bodei, Mark Kidd, Margot Tesselaar, Valentina Ambrosini, Richard P Baum, Matthew Kulke, Marianne Pavel, Jaroslaw Cwikla, Ignat Drozdov, Massimo Falconi, Nicola Fazio, Andrea Frilling, Robert Jensen, Klaus Koopmans, Tiny Korse, Dik Kwekkeboom, Helmut Maecke, Giovanni Paganelli, Ramon Salazar, Stefano Severi, Jonathan Strosberg, Vikas Prasad, Aldo Scarpa, Ashley Grossman, Annemeik Walenkamp, Mauro Cives, Irene Virgolini, Andreas Kjaer and Irvin M Modlin

of radioactive somatostatin analogs ( 10 ). Strategies include somatostatin receptor agonists, ‘targeted’ agents (mTOR inhibitors and VEGF antagonists), immunotherapy (interferon), cytotoxic chemotherapy, peptide receptor radionuclide therapy (PRRT

Open access

Anna Malczewska, Magdalena Witkowska, Karolina Makulik, Agnes Bocian, Agata Walter, Joanna Pilch-Kowalczyk, Wojciech Zajęcki, Lisa Bodei, Kjell Oberg and Beata Kos-Kudła

-SSA-PET/CT, has improved the sensitivity of NET detection ( 15 ), especially in extra-hepatic localization. It has benefit in the assessment of eligibility for peptide receptor radionuclide therapy (PRRT) and somatostatin analogs (SSAs). Its accuracy, however, is

Open access

Anna-Pauliina Iivonen, Johanna Känsäkoski, Atte Karppinen, Leena Kivipelto, Camilla Schalin-Jäntti, Auli Karhu and Taneli Raivio

demonstrated in a subset of exceptionally large, somatostatin analog (SMS)-resistant somatotropinomas ( 25 ). Wnt pathway inhibitors have been found to be downregulated in GH-secreting pituitary tumors ( 26 , 27 ), suggesting that Wnt signaling, possibly